Alnylam to Webcast R&D Day on Thursday, November 12, 2009

CAMBRIDGE, Mass.--(Business Wire)--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that it will webcast its upcoming R&D Day live on the
"Investors" section of the company`s website at www.alnylam.com.

Alnylam scientists and management will review and provide updates on Alnylam
platform advancements, delivery strategies, and pipeline of novel RNAi
therapeutics. In addition, Alnylam will host two guest speakers:

* Professor Allan R. Glanville, Director of Thoracic Medicine and Medical
Director Lung Transplantation, St. Vincent`s Hospital, Sydney, will discuss
respiratory syncytial virus (RSV) infection in the lung transplant patient
population; and,
* Professor Philip N. Hawkins, National Amyloidosis Centre, Division of
Medicine, and University College London Medical School Royal Free Hospital, will
discuss transthyretin (TTR)-mediated amyloidosis.

Alnylam`s R&D Day will be held on Thursday, November 12, 2009 from 8:30 a.m. to
12:00 p.m. ET at the Loews Regency Hotel in New York City. An audio replay of
the event will be posted on the Alnylam website approximately three hours after
the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is applying its therapeutic expertise in
RNAi to address significant medical needs, many of which cannot effectively be
addressed with small molecules or antibodies, the current major classes of
drugs. Alnylam is leading the translation of RNAi as a new class of innovative
medicines with peer-reviewed research efforts published in the world`s top
scientific journals including Nature, Nature Medicine, and Cell. The company is
leveraging these capabilities to build a broad pipeline of RNAi therapeutics;
its most advanced program is in Phase II human clinical trials for the treatment
of respiratory syncytial virus (RSV) infection and is partnered with Cubist and
Kyowa Hakko Kirin. In addition, the company is developing RNAi therapeutics for
the treatment of a wide range of disease areas, including liver cancers,
hypercholesterolemia, Huntington`s disease, and TTR amyloidosis. The company`s
leadership position in fundamental patents, technology, and know-how relating to
RNAi has enabled it to form major alliances with leading companies including
Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist.
To reflect its outlook for key scientific, clinical, and business initiatives,
Alnylam established "RNAi 2010" in January 2008 which includes the company`s
plan to significantly expand the scope of delivery solutions for RNAi
therapeutics, have four or more programs in clinical development, and to form
four or more new major business collaborations, all by the end of 2010. Alnylam
and Isis are joint owners of Regulus Therapeutics Inc., a company focused on the
discovery, development, and commercialization of microRNA-based therapeutics.
Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For
more information, please visit www.alnylam.com.

Alnylam Pharmaceuticals, Inc.
Cynthia Clayton (Investors)
617-551-8207
or
Kathryn Morris (Media)
Yates Public Relations
845-635-9828

Copyright Business Wire 2009